Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01519011 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01519011 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 34 participants.
The verdict
NCT01519011, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the pharmacokinetics of oral azacitidine when administered once daily as two 150-mg tablets, including the effect of food, and to evaluate the bioavailability of oral azacitidine 300-mg when administered as two 150-mg tablets relative to three 100-mg tablets.
Interventions
- DRUG oral azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-02-07 |
| Est. Completion | 2015-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01519011
The ClinicalTrials.gov registry entry for NCT01519011 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which oral azacitidine is the first listed.
NCT01519011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01519011 about?
NCT01519011 is a clinical study titled "Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine". The primary purpose of this study is to evaluate the pharmacokinetics of oral azacitidine when administered once daily as two 150-mg tablets, including the effect of food, and to evaluate the bioavailability of oral azacitidine 300-mg when administered as two 150-mg tablets relative to three 100-mg ...
What is the current status of trial NCT01519011?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2012-02-07. Estimated completion is 2015-05-12.
What interventions are being tested in trial NCT01519011?
The interventions under investigation include: oral azacitidine (DRUG).
Who is sponsoring clinical trial NCT01519011?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.